Friday, April 10, 2015 10:40:10 PM
Published: Apr 9, 2015 8:30 a.m. ET
NEW YORK, NY, Apr 09, 2015 (Marketwired via COMTEX) -- Daxor (nyse mkt:DXR) has received approval from the US Patent Office for a Total Body Albumin Analyzer, US Patent # 9,002,656. The patent for the total body albumin analyzer is the first one issued for an instrument to measure the total albumin within the human body. Albumin is the major carrier molecule in the human body for hundreds of metabolic products such as hormones. Albumin is also the major protein responsible for maintaining blood pressure within the body. Many diseases such as congestive heart failure, diabetes, kidney disease, involve loss of albumin concentration within the circulation. Albumin is a vastly underutilized therapeutic agent derived from human blood. The ability to precisely quantify the total amount of albumin in an individual patient should provide opportunities for its therapeutic use in conditions where its absence leads to major blood volume derangements. The total body albumin measurement is performed in conjunction with a blood volume measurement. The ability to perform this test is an upgrade to the Blood Volume Analyzer and will not require the patient to have an additional injection. Co-inventors are Dr. Joseph Feldschuh and Jonathan Feldschuh.
Daxor has also been issued a patent covering new technology used in the automated Blood Volume Analyzer US Patent # 9,002,657. The test for measuring blood volume currently uses five sample points to provide an accurate measurement of a subject's blood volume by measuring the dilution of a tracer in the subject's bloodstream over a thirty-five minute period. The new patented method uses statistical algorithms to allow for the accurate, automatic calculation of a blood volume, even if one of the five samples is not in line with the others. This eliminates the need for technician interpretation. The algorithm is already in use in the current version of the BVA-100 Analyzer, and enables robust, accurate results. Co-inventors are Dr. Joseph Feldschuh and Jonathan Feldschuh.
Dr. Joseph Feldschuh stated that "The ability to precisely quantify the amount of albumin in a specific patient should significantly increase the utilization of this essential blood protein. Albumin for intravenous use is currently supplied by Baxter. Conditions such as septic shock, congestive heart failure, kidney and liver failure may result in a collapse of the circulation. Appropriate use of intravenous albumin based on quantitative measurements has the potential to save the lives of patients who might otherwise not survive. It is my belief that lack of ability to accurately quantify the amount of albumin in a patient's body has been a major factor in its under-utilization. It is our hope that this breakthrough will lead to significantly improved treatment of critically ill patients."
To learn more about Daxor, please visit www.Daxor.com.
http://www.marketwatch.com/story/daxor-receives-two-patents-one-for-measurement-of-total-body-albumin-and-a-second-patent-for-improved-accuracy-of-blood-volume-measurement-2015-04-09
Recent DXR News
- New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™) • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24 • GlobeNewswire Inc. • 04/01/2024 12:00:00 PM
- Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024 • GlobeNewswire Inc. • 03/22/2024 12:00:00 PM
- Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023 • GlobeNewswire Inc. • 03/18/2024 06:18:00 PM
- Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders • GlobeNewswire Inc. • 03/18/2024 06:18:00 PM
- Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base • GlobeNewswire Inc. • 03/11/2024 12:00:00 PM
- Form NT-NCSR/A - Notice under Exchange Act Rule 12b-25 of inability to timely file Form N-CSR (annual or semi-annual report): [Amend] • Edgar (US Regulatory) • 03/08/2024 06:49:31 PM
- Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients • GlobeNewswire Inc. • 03/08/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 09:18:32 PM
- Form NT-NCSR/A - Notice under Exchange Act Rule 12b-25 of inability to timely file Form N-CSR (annual or semi-annual report): [Amend] • Edgar (US Regulatory) • 02/29/2024 10:28:32 PM
- Form NT-NCSR - Notice under Exchange Act Rule 12b-25 of inability to timely file Form N-CSR (annual or semi-annual report) • Edgar (US Regulatory) • 02/29/2024 09:15:19 PM
- Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions • GlobeNewswire Inc. • 02/12/2024 01:00:00 PM
- Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100® Blood Volume Diagnostic Across the U.S. at Existing Accounts • GlobeNewswire Inc. • 02/07/2024 01:00:00 PM
- Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting • GlobeNewswire Inc. • 01/29/2024 01:00:00 PM
- Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress • GlobeNewswire Inc. • 01/16/2024 01:00:00 PM
- DAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES • GlobeNewswire Inc. • 01/09/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 01:52:42 PM
- Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer • GlobeNewswire Inc. • 01/02/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2023 08:48:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 02:00:56 AM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM